REVOLUTION Medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. Our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. We pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
REVOLUTION Medicines exploits inventions by the company’s lead founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, who developed a transformative method for synthesizing chemical compounds including complex natural products, analogs or original small molecules that are pharmaceutically optimized. REVOLUTION Medicines has entered into an exclusive licensing agreement with the University of Illinois to practice this technology.
REVOLUTION Medicines’ integrated product engine builds upon and expands these modular synthesis methods to power the focused and efficient assembly of simple "chemical building blocks" into refined chemical structures that exhibit optimized pharmacologic properties. In addition, we deploy advanced biologic assays, biophysical approaches and computational methods to enhance our understanding of disease targets and to drive advanced drug discovery.
Headquartered in Redwood City, Calif., at the intersection of Silicon Valley and the birthplace of biotechnology, REVOLUTION Medicines is a private company launched with $70 million in Series A financing from Third Rock Ventures and The Column Group.